Is it possible that an iPhone app can help diagnose sleep apnea? Read on.
ResApp Health’s SleepCheckRx[i] app has received FDA 510(k) clearance[ii] as a prescription-only software-as-a-medical device. Obtaining this FDA clearance enables ResApp to commercially market the test in the United States.
SleepCheckRx is an at-home sleep test that screens adults for the risk of moderate to severe obstructive sleep apnea by analyzing breathing and snore sounds. These sounds are recorded on an Apple iPhone and analyzed through a proprietary application. The app requires no accessories or hardware other than an iPhone to make an assessment. ResApp is planning to solicit 510(k) clearance for Android devices in the future.
ResApp Health is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware.
Of note, ResApp’s regulatory-approved, and clinically validated products include:
- ResAppDx – a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings
- SleepCheck, a smartphone application that allows consumers to self-assess their risk of sleep apnea.
Both products are CE Marked in Europe[iii] and TGA-approved in Australia.[iv]
SleepCheckRx will only be available to patients with a prescription from their healthcare provider. Patients will be provided with a specific code allowing them to download SleepCheckRx from the App Store, with their results uploaded to a healthcare provider portal.
According to the ResApp Health, in an at-home clinical trial of 220 patients comparing SleepCheckRx with simultaneous polysomnography, the SleepCheckRx algorithms correctly identified 89.3% of patients with moderate to severe obstructive sleep apnea (AHI greater than or equal to 15/hour) and achieved a specificity of 77.6%.
Tony Keating, CEO and managing director of ResApp Health, says in a release, “We are delighted to have secured FDA clearance for SleepCheckRx. With more than 20 million American adults suffering from sleep apnea and the majority of those not knowing that they have the condition, this clearance unlocks a significant market opportunity for ResApp. By using SleepCheckRx, physicians will have the opportunity to screen their patients conveniently and quickly for sleep apnea, helping their patients take the first step to getting treatment.”
We are dedicated to meeting the educational needs for professionals in the sleep medicine and respiratory therapists in the sleep & respiratory medicine industries.
Our Courses are approved by …
- the American Association for Respiratory Care (AARC)
- the Board of Registered Polysomnographic Technologists (BRPT)
- and the Canadian Society Of Respiratory Therapists (CSRT)
FOOTNOTES:
